Stock Purchase. On the Effective Date, GSK will purchase 4,000,000 shares of Theravance Series E Preferred Stock at a price of U.S.$10.00 per share for total consideration of Forty Million United States Dollars (U.S. $40,000,000). Such purchase will be made pursuant to the Preferred Stock Purchase Agreement attached hereto as Schedule 6.1.2.
Appears in 4 contracts
Samples: Collaboration Agreement (Theravance Inc), Collaboration Agreement (Theravance Inc), Preferred Stock Purchase Agreement (Theravance Inc)
